Sagent Pharmaceuticals Announces Launch of Irinotecan Hydrochloride Injection in Single Dose Vials

Loading...
Loading...
Sagent Pharmaceuticals, Inc.
SGNT
today announced the launch of Irinotecan Injection, the generic form of the chemotherapy drug Camptosar®, in two latex free, preservative free single dose vials. According to IMS data for the twelve-months ended March 2012, the U.S. market for Irinotecan approximated $28 million. As with all products in Sagent's portfolio, Irinotecan features the company's PreventIV Measures^SM packaging and labeling designed to aid in the reduction of medication errors.
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...